Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.81 |
| ▸ | MEN1 | O00255 | 3/20 | 0.81 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.72 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.72 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.72 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | NPC1 | O15118 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7278495 | 0.94 | PLAAT3 (0.74) | KMT2AMEN1PLAAT3PLAAT5PLAAT2 | |
| SCHEMBL4022887 | 0.93 | KMT2A (0.87) | KMT2AMEN1ALDH1A1LMNAMAPT | |
| SCHEMBL4026595 | 0.92 | PLAAT3 (0.80) | KMT2AMEN1PLAAT3PLAAT5PLAAT2 | |
| SCHEMBL17117415 | 0.91 | PLAAT3 (0.74) | KMT2AMEN1PLAAT3PLAAT5PLAAT2 | |
| SCHEMBL10436226 | 0.90 | PLAAT3 (0.73) | KMT2AMEN1PLAAT3PLAAT5PLAAT2 | |
| SCHEMBL9311815 | 0.89 | KMT2A (0.72) | KMT2AMEN1ALDH1A1LMNAMAPT | |
| SCHEMBL4024309 | 0.89 | KMT2A (0.80) | KMT2AMEN1ALDH1A1LMNAMAPT | |
| SCHEMBL4023394 | 0.88 | KMT2A (0.79) | KMT2AMEN1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL8828335 | 0.88 | KMT2A (0.64) | KMT2AMEN1PLAAT3PLAAT5PLAAT2 | |
| SCHEMBL10452171 | 0.88 | KMT2A (0.64) | KMT2AMEN1PLAAT3PLAAT5PLAAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3209639-B1 | COMPOUNDS AS ANTI-MALARIALS AND THEIR PROCESS OF PREPARATION | COUNCIL SCIENT IND RES (IN) | 2020-09-16 | — | — | EP | disclosed |
| CN-100393703-C | 1,2,3,4-tetrahydroisoquinoline derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2008-06-11 | — | — | CN | disclosed |
| EP-1274687-B1 | 1,2,3,4- TETRAHYDROISOQUINOLINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2005-01-05 | — | — | EP | disclosed |
| US-6703392-B2 | OREXIN RECEPTOR ANTAGONISTS FOR OBESITY OR SLEEPING DISORDER TREATMENT | ACTELION PHARMACEUTICALS LTD. (CH) | 2004-03-09 | — | — | US | disclosed |
| US-20030176415-A1 | 1,2,3,4-tetrahydroisoquinoline derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2003-09-18 | — | — | US | disclosed |
| CN-1416420-A | 1,2,3, 4-tetrahydroisoquinoline derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2003-05-07 | — | — | CN | disclosed |
| EP-1274687-A1 | 1,2,3,4- TETRAHYDROISOQUINOLINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2003-01-15 | — | — | EP | disclosed |
| WO-2001068609-A1 | 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176415-A1 | 1,2,3,4-tetrahydroisoquinoline derivatives | HCRTR2, HCRTR1, NPY2R | KMT2A 1396/4885MEN1 764/4885PLAAT3 2201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.